Differential protein expression and enriched pathways in pediatric sepsis: identification of novel brain-associated biomarkers revealed through proteomic profiling

Topic/Product:
CNS Disease Panel 120, Inflammation
Disease Area:
Sepsis
Sample Type:
Plasma

Abstract

Background

Sepsis, defined by confirmed or suspected infection with systemic inflammatory response syndrome, requires robust biomarker identification. Proteomics enables protein quantification and expression analysis across disease states. This study investigated differential protein expression patterns, particularly brain-associated proteins, between sepsis patients and healthy controls, while evaluating temporal variations and relevant molecular pathways.

Methods

Study participants were prospectively enrolled based on established pediatric sepsis criteria with clinical and blood samples collected. Plasma protein concentrations were quantified using Nucleic Acid Linked Immuno-Sandwich Assay methodology. Statistical analyses incorporated conventional statistics, bioinformatics and machine learning approaches.

Results

The study cohorts comprised 23 age- and sex-matched participants: pediatric sepsis patients (median 11 years, IQR 9.5–14) and healthy controls (median 11 years, IQR 7.8–13; P = 0.809). Analyses revealed 59 differentially expressed proteins (DEPs) on Pediatric Intensive Care Unit Day 1 (PICU D1). Random Forest Classification (RFC) with Boruta feature selection identified 29 proteins that facilitated distinct group stratification. Comparison between PICU D1 and D3 samples yielded 34 DEPs, with RFC and Boruta feature selection isolating 9 discriminatory proteins. Multiple proteins were correlated with PELOD-2 scores and mortality (P < 0.05). Novel brain-associated proteins demonstrated significant differential expression patterns between PICU D1 and healthy controls, and over 3 days of PICU stay in sepsis patients. PICU D1 samples demonstrated significant pathway upregulation when compared to healthy controls, including “Signaling by Interleukins”, “Cytokine Signaling in Immune system”, and “Interleukin-10 signaling”. By PICU D3, pathways associated with “Generic Transcription Pathway”, “RNA Polymerase II Transcription”, and “Gene expression (Transcription)” exhibited significant downregulation. Protein-protein interaction network analysis revealed TNF and IL1B as critical bridging proteins linking inflammatory and neurological processes. Disease enrichment analysis demonstrated significant over-representation of respiratory pathology-associated genes, with respiratory failure and adult respiratory distress syndrome as the most enriched categories.

Conclusions

Our investigation revealed distinct proteomic signatures in inflammatory and transcriptional pathways, including brain-associated processes, that differentiated pediatric sepsis patients from healthy control participants and exhibited temporal dynamics. The identification of TNF and IL1B as bridging proteins between systemic inflammation and neurological processes, combined with respiratory-centric disease enrichment patterns, provides mechanistic insights into sepsis pathophysiology. These alterations may provide insight into the mechanisms underlying sepsis-associated encephalopathy and lingering cognitive impairment in sepsis survivors, warranting further investigation in future studies. The identified molecular signatures present potential diagnostic and prognostic biomarkers for pediatric sepsis management.

Authors & Affiliations

Vincenzo Stranges¹, David Tweddell², Enis Cela³, Maria Morello⁴, Mark Daley²⁵, Gediminas Cepinskas⁶⁷⁸, and Douglas D. Fraser³⁸⁹¹⁰¹¹¹²

¹ Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Rome, Italy
² Computer Science, Western University, London, ON, Canada
³ Physiology and Pharmacology, Western University, London, ON, Canada
⁴ Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
⁵ Epidemiology and Biostatistics, Western University, London, ON, Canada
⁶ Medical Biophysics, Western University, London, ON, Canada
⁷ Anatomy and Cell Biology, Western University, London, ON, Canada
⁸ London Health Sciences Centre Research Institute, 800 Commissioners Road East, London, ON, Canada
⁹ Pediatrics, Western University, London, ON, Canada
¹⁰ Clinical Neurological Sciences, Western University, London, ON, Canada
¹¹ Children’s Health Research Institute, London, ON, Canada
¹² GSK Chair in Clinical Pharmacology, Western University, London, ON, Canada

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.